BACKGROUND: Initial pharmacokinetic (PK) studies of discovery compounds are conducted in mice to demonstrate exposure prior to conducting efficacy studies. PK information obtained from a single mouse by serial blood microsampling, dried blood spot collection and analyses using microbore (1 mm internal diameter column) LC-MS/MS is presented. Ex vivo blood to plasma concentration ratios (BPRs) from mouse PK studies were compared with in vitro BPRs for 15 compounds. RESULTS: Two compounds were orally dosed and blood was collected at time points via serial blood sampling. The calculated PK parameters (AUC, T(max) and C(max)) were comparable across liquid blood, dried blood spot and plasma matrices. The BPR results from both methods were comparable. CONCLUSION: Serial blood microsampling has led to reduced animal and compound usage with improved PK data. Ex vivo BPR is suitable in a discovery setting. Microbore LC-MS/MS is well suited in instances where sample volume is limited, and enables faster analyses, reduced solvent use, and less frequent MS source cleaning.
BACKGROUND: Initial pharmacokinetic (PK) studies of discovery compounds are conducted in mice to demonstrate exposure prior to conducting efficacy studies. PK information obtained from a single mouse by serial blood microsampling, dried blood spot collection and analyses using microbore (1 mm internal diameter column) LC-MS/MS is presented. Ex vivo blood to plasma concentration ratios (BPRs) from mouse PK studies were compared with in vitro BPRs for 15 compounds. RESULTS: Two compounds were orally dosed and blood was collected at time points via serial blood sampling. The calculated PK parameters (AUC, T(max) and C(max)) were comparable across liquid blood, dried blood spot and plasma matrices. The BPR results from both methods were comparable. CONCLUSION: Serial blood microsampling has led to reduced animal and compound usage with improved PK data. Ex vivo BPR is suitable in a discovery setting. Microbore LC-MS/MS is well suited in instances where sample volume is limited, and enables faster analyses, reduced solvent use, and less frequent MS source cleaning.
Authors: Christopher Evans; Mark Arnold; Peter Bryan; Jeffrey Duggan; Christopher A James; Wenkui Li; Steve Lowes; Luca Matassa; Timothy Olah; Philip Timmerman; Xiaomin Wang; Enaksha Wickremsinhe; John Williams; Eric Woolf; Patricia Zane Journal: AAPS J Date: 2014-12-09 Impact factor: 4.009
Authors: Kashyap Patel; Julie A Simpson; Kevin T Batty; Sophie Zaloumis; Carl M Kirkpatrick Journal: Br J Clin Pharmacol Date: 2015-01 Impact factor: 4.335
Authors: Jeremy Drolet; Vladimir Tolstikov; Brian A Williams; Bennett P Greenwood; Collin Hill; Vivek K Vishnudas; Rangaprasad Sarangarajan; Niven R Narain; Michael A Kiebish Journal: Metabolites Date: 2017-07-15
Authors: Fei Gao; Justice McDaniel; Emily Y Chen; Hannah E Rockwell; Jeremy Drolet; Vivek K Vishnudas; Vladimir Tolstikov; Rangaprasad Sarangarajan; Niven R Narain; Michael A Kiebish Journal: Nutr Metab (Lond) Date: 2017-03-20 Impact factor: 4.169
Authors: Diana Caridha; Brian Vesely; Katrien van Bocxlaer; Byron Arana; Charles E Mowbray; Sima Rafati; Silvia Uliana; Rosa Reguera; Mara Kreishman-Deitrick; Richard Sciotti; Pierre Buffet; Simon L Croft Journal: Int J Parasitol Drugs Drug Resist Date: 2019-06-20 Impact factor: 4.077